GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (HAM:407) » Definitions » Other Operating Expense

Sensei Biotherapeutics (HAM:407) Other Operating Expense : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Other Operating Expense?

Sensei Biotherapeutics's Other Operating Expense for the three months ended in Mar. 2024 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Sensei Biotherapeutics's quarterly Other Operating Expense declined from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then stayed the same from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).

Sensei Biotherapeutics's annual Other Operating Expense declined from Dec. 2021 (€-0.00 Mil) to Dec. 2022 (€-0.00 Mil) but then increased from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).


Sensei Biotherapeutics Other Operating Expense Historical Data

The historical data trend for Sensei Biotherapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Other Operating Expense Chart

Sensei Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial - - - - -

Sensei Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sensei Biotherapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sensei Biotherapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensei Biotherapeutics (HAM:407) Business Description

Traded in Other Exchanges
Address
1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Sensei Biotherapeutics (HAM:407) Headlines

No Headlines